Digital twins techniques in the design of Alzheimer’s disease clinical trials: an application to the Internet‐Based Conversational Engagement Clinical Trial (I‐CONECT)

Abstract

Background: With U.S. Food and Drug Administration (FDA)‐approved anti‐amyloid, partially disease‐modifying treatments now available, the ethical justification for randomly assigning patients to placebo has become controversial.